Intra-Cellular Stock Buy Hold or Sell Recommendation


USD 55.17  1.91  3.35%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Intra-Cellular Ther is 'Buy'. Macroaxis provides Intra-Cellular Ther buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ITCI positions. The advice algorithm takes into account all of Intra-Cellular Ther's available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from Intra-Cellular Ther's buy-and-hold perspective. Please see Intra-Cellular Ther Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Intra-Cellular and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Intra-Cellular Ther.

Execute Intra-Cellular Ther Buy or Sell Advice

The Intra-Cellular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Intra-Cellular Ther. Macroaxis does not own or have any residual interests in Intra-Cellular Ther or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Intra-Cellular Ther's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Intra-Cellular TherBuy Intra-Cellular Ther


Very steadyDetails

Hype Condition

Low keyDetails

Current Valuation

Fairly ValuedDetails

Odds of Distress


Economic Sensitivity

Almost mirrors the marketDetails

Analyst Consensus


Financial Strenth (F Score)


Financial Leverage


Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Intra-Cellular Ther has a Risk Adjusted Performance of (0.023355), Jensen Alpha of 0.0752, Total Risk Alpha of 0.4834 and Treynor Ratio of (0.11)
Our investment recommendation module provides unbiased trade recommendations that can be used to complement current average analyst sentiment on Intra-Cellular Ther. Our investment recommendation engine provides an advice for the firm potential to grow from the perspective of an investor's risk tolerance and investing horizon. To make sure Intra-Cellular Ther is not overpriced, please check out all Intra-Cellular Ther fundamentals, including its book value per share, total asset, and the relationship between the cash per share and price to earnings to growth . Given that Intra-Cellular Ther has a price to earning of (6.56) X, we strongly advise you to confirm Intra-Cellular Ther market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Intra-Cellular Ther Trading Alerts and Improvement Suggestions

Intra-Cellular Ther generated a negative expected return over the last 90 days
Intra-Cellular Ther has high historical volatility and very poor performance
Intra-Cellular Ther has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 83.8 M. Net Loss for the year was (284.13 M) with loss before overhead, payroll, taxes, and interest of (13.08 M).
Intra-Cellular Ther currently holds about 412.33 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Intra-Cellular Ther has a frail financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from Premarket Movers MSP Recovery, Carnival, McCormick Co - MarketWatch

Intra-Cellular Ther current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intra-Cellular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intra-Cellular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price71.20
Target Median Price70.00
Target High Price90.00
Recommendation Mean1.70
Number Of Analyst Opinions10
Target Low Price57.00
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Intra-Cellular Ther Returns Distribution Density

The distribution of Intra-Cellular Ther's historical returns is an attempt to chart the future uncertainty of Intra-Cellular Ther's future price movements. The chart of the probability distribution of Intra-Cellular Ther stock daily returns describes the distribution of returns around its average expected value. We use Intra-Cellular Ther price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Intra-Cellular Ther returns is essential to provide solid investment advice for Intra-Cellular Ther stock.
Mean Return-0.09Value At Risk-5.74
Potential Upside5.38Standard Deviation4.33
 Return Density 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Intra-Cellular Ther historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Intra-Cellular Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Intra-Cellular Ther is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intra-Cellular Ther backward and forwards among themselves. Intra-Cellular Ther's institutional investor refers to the entity that pools money to purchase Intra-Cellular Ther's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares11 M670.3 M
Vanguard Group IncCommon Shares7.8 M476.6 M
Wasatch Advisors IncCommon Shares7.5 M457.6 M
Blackrock IncCommon Shares6.5 M395.9 M
Wellington Management Group LlpCommon Shares4.1 M248.5 M
Bellevue Group AgCommon Shares3.4 M209.9 M
Marshall Wace LlpCommon Shares2.5 M154.2 M
Note, although Intra-Cellular Ther's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Intra-Cellular Ther Cash Flow Accounts

201720182019202020212022 (projected)
Capital Expenditure(723.43 K)(391.27 K)(700.39 K)(266.72 K)(325.74 K)(351.45 K)
Depreciation Amortization and Accretion213.87 K368.67 K477.12 K528.12 K533.36 K425.1 K
Net Cash Flow or Change in Cash and Cash Equivalents(10.85 M)17.16 M52.69 M(46.19 M)32.32 M34.87 M
Issuance Purchase of Equity Shares162.36 M685.19 K3.24 M664.18 M11.52 M11.82 M
Net Cash Flow from Financing162.36 M685.19 K3.24 M664.18 M11.52 M11.82 M
Net Cash Flow from Investing(92.72 M)134.64 M177.44 M(480.3 M)280.34 M302.48 M
Net Cash Flow Investment Acquisitions and Disposals(91.99 M)135.03 M178.14 M(480.03 M)280.67 M302.83 M
Net Cash Flow from Operations(80.49 M)(118.17 M)(127.98 M)(230.07 M)(259.54 M)(266.37 M)
Share Based Compensation14.83 M17.59 M20.98 M24.33 M34.48 M37.2 M

Intra-Cellular Ther Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Intra-Cellular Ther or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Intra-Cellular Ther stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Intra-Cellular stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW0.92
Overall volatility
Information ratio 0.0207

Intra-Cellular Ther Volatility Alert

Intra-Cellular Ther exhibits very low volatility with skewness of 2.54 and kurtosis of 13.3. However, we advise investors to further study Intra-Cellular Ther technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Intra-Cellular Ther's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Intra-Cellular Ther's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Intra-Cellular Ther Implied Volatility

Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.

Intra-Cellular Ther Fundamentals Vs Peers

Comparing Intra-Cellular Ther's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Intra-Cellular Ther's direct or indirect competition across all of the common fundamentals between Intra-Cellular Ther and the related equities. This way, we can detect undervalued stocks with similar characteristics as Intra-Cellular Ther or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Intra-Cellular Ther's fundamental indicators could also be used in its relative valuation, which is a method of valuing Intra-Cellular Ther by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare Intra-Cellular Ther to competition
FundamentalsIntra-Cellular TherPeer Average
Return On Equity(52.87) %(0.31) %
Return On Asset(29.58) %(0.14) %
Operating Margin(340.90) %(5.51) %
Current Valuation4.35 B16.62 B
Shares Outstanding81.46 M571.82 M
Shares Owned by Insiders2.51 %10.09 %
Shares Owned by Institutions86.56 %39.21 %
Number of Shares Shorted3.34 M4.71 M
Price to Earning(6.56) X28.72 X
Price to Book9.68 X9.51 X
Price to Sales56.28 X11.42 X
Revenue83.8 M9.43 B
Gross Profit(13.08 M)27.38 B
EBITDA(285.15 M)3.9 B
Net Income(284.13 M)570.98 M
Cash and Equivalents412.33 M2.7 B
Cash per Share4.41 X5.01 X
Total Debt25.41 M5.32 B
Debt to Equity0.06 %48.70 %
Current Ratio8.76 X2.16 X
Book Value Per Share5.98 X1.93 K
Cash Flow from Operations(259.54 M)971.22 M
Short Ratio3.65 X4.00 X
Earnings Per Share(3.20) X3.12 X
Price to Earnings To Growth(0.08) X4.89 X
Number of Employees51218.84 K
Market Capitalization4.72 B19.03 B
Total Asset542.57 M29.47 B
Retained Earnings(728.79 M)9.33 B
Working Capital401.13 M1.48 B
Current Asset541.82 M9.34 B
Current Liabilities140.69 M7.9 B
   Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3 [view details]

Intra-Cellular Ther Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Intra-Cellular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution62623.16
Daily Balance Of Power(0.48)
Rate Of Daily Change0.97
Day Median Price55.13
Day Typical Price55.14
Market Facilitation Index0.0
Price Action Indicator(0.91)

About Intra-Cellular Ther Buy or Sell Advice

When is the right time to buy or sell Intra-Cellular Ther? Buying financial instruments such as Intra-Cellular Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Intra-Cellular Ther investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2021 2022 (projected)
Receivables20.16 M21.75 M
Inventories7.95 M7.34 M

Use Investing Ideas to Build Portfolios

In addition to having Intra-Cellular Ther in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Tech Growth Thematic Idea Now

Tech Growth
Tech Growth Theme
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 65 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
View All  Next Launch Tech Growth
Please see Intra-Cellular Ther Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.